Home » Stocks » DMAC

DiaMedica Therapeutics Inc. (DMAC)

Stock Price: $6.50 USD 0.03 (0.46%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 122.11M
Revenue (ttm) n/a
Net Income (ttm) -13.49M
Shares Out 18.79M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $6.50
Previous Close $6.47
Change ($) 0.03
Change (%) 0.46%
Day's Open 6.45
Day's Range 6.31 - 6.71
Day's Volume 112,094
52-Week Range 3.77 - 10.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 week ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

2 weeks ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

3 weeks ago - Business Wire

ATTO, DMAC, DG, GEL, and IAG have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2021

Other stocks mentioned: ATTO, DG, GEL, IAG
3 weeks ago - Zacks Investment Research

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 month ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

2 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney d...

2 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced tha...

2 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

2 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

2 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced tha...

2 months ago - Business Wire

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...

Other stocks mentioned: BHC, IBIO, ONCY, OTLK
2 months ago - Benzinga

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced tha...

4 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Comp...

5 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company su...

5 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological d...

5 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, t...

6 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders...

6 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4th...

6 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4th Annual Best Ideas Growth (BIG4) Confere...

8 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dosing of the...

8 months ago - Business Wire

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders...

9 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registered public o...

9 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, August 11th.

9 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public o...

9 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten p...

9 months ago - Business Wire

DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.

10 months ago - Benzinga

DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG...

1 year ago - GlobeNewsWire

MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in...

1 year ago - GlobeNewsWire

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of the thinly traded nano-cap biotech DiaMedica Therapeutics Inc (NASDAQ: DMAC) were rallying strongly Thursday.

1 year ago - Benzinga

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeu... [Read more...]

Industry
Biotechnology
Founded
2000
Stock Exchange
NASDAQ
Ticker Symbol
DMAC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is 25.33, which is an increase of 289.69% from the latest price.

Price Target
$25.33
(289.69% upside)
Analyst Consensus: Strong Buy